DEPARTMENT OF DEFENSE

Department of the Army

Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Preoperative Recommendations Engine

AGENCY: Department of the Army, DoD.

ACTION: Notice.

SUMMARY: Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/849,910, entitled “Preoperative Recommendations Engine,” filed on January 14, 2013. The United States Government, as represented by the Secretary of the Army, has rights to this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702–5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619–6664, both at telefax (301) 619–5034.

SUPPLEMENTARY INFORMATION: The invention relates to a system that compiles patient-specific, evidenced-based perioperative recommendations for the consulting surgical specialist, and creates medication management instructions directly for the patients use. Its modular architecture is easily maintained and updated, assuring currency with cutting-edge perioperative practices. Its adoption facilitates the implementation of accepted best practices, potentially minimizing perioperative risk and optimizing surgical outcomes.

Brenda S. Bowen, Army Federal Register Liaison Officer.

DEPARTMENT OF DEFENSE

Department of the Army

Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies

AGENCY: Department of the Army, DoD.

ACTION: Notice.

SUMMARY: Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/762,543, entitled “Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies,” filed on February 8, 2013. The United States Government, as represented by the Secretary of the Army, has rights to this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702–5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619–6664, both at telefax (301) 619–5034.

SUPPLEMENTARY INFORMATION: The invention relates to Antibody-Dependent cellular cytotoxicity (ADCC)-mediating antibodies, and, in particular, to ADCC-mediating antibodies [and fragments thereof] suitable for use, for example, in reducing the risk of HIV–1 infection in a subject. The invention further relates to compositions comprising such antibodies or antibody fragments.

Brenda S. Bowen, Army Federal Register Liaison Officer.

DEPARTMENT OF DEFENSE

Department of the Army

Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Therapeutic Peptides That Inhibit Rift Valley Fever Virus, Ebola Virus, Andes Virus and Vesicular Stomatitis Virus Infectivity, Compositions and Methods

AGENCY: Department of the Army, DoD.

ACTION: Notice.

SUMMARY: Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/733,966, entitled “Therapeutic Peptides that Inhibit Rift Valley Fever Virus, Ebola Virus, Andes Virus and Vesicular Stomatitis Virus Infectivity, Compositions and Methods,” filed on December 6, 2012. The United States Government, as represented by the Secretary of the Army, has rights to this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702–5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619–6664, both at telefax (301) 619–5034.

SUPPLEMENTARY INFORMATION: The invention relates to novel, broad spectrum, antiviral peptides, compositions containing one or more of these and their use for the prophylactic treatment against and/or therapeutic treatment of infection by hemorrhagic fever viruses (HFVs), such as Rift Valley fever virus (RVFV), Ebola virus (EBOV), and Andes virus (ANDV). Additionally, these peptides were capable of inhibiting vesicular stomatitis virus (VSV), and agricultural pathogen with limited therapeutic availability.

Brenda S. Bowen, Army Federal Register Liaison Officer.